(Q40169260)

18 September 2017

title

Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model (English)

1 reference

18 September 2017

Hasan C Ugur

1

1 reference

18 September 2017

Naren Ramakrishna

2

1 reference

18 September 2017

Lorenzo Bello

3

1 reference

18 September 2017

Lata G Menon

4

1 reference

18 September 2017

Seung-Ki Kim

5

1 reference

18 September 2017

Peter M Black

6

1 reference

18 September 2017

Rona S Carroll

7

1 reference

18 September 2017

publication date

20 February 2007

1 reference

Journal of Neuro-Oncology

18 September 2017

published in

1 reference

18 September 2017

volume

83

1 reference

18 September 2017

issue

3

1 reference

18 September 2017

page(s)

267-275

1 reference

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

18 September 2017

cites work

1 reference

12 December 2020

Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant

1 reference

12 December 2020

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

12 December 2020

Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo

1 reference

12 December 2020

Modulation of radiation response by histone deacetylase inhibition

1 reference

12 December 2020

1 reference

12 December 2020

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells

1 reference

12 December 2020

Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.

1 reference

12 December 2020

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

12 December 2020

Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced

1 reference

12 December 2020

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo

1 reference

12 December 2020

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

1 reference

12 December 2020

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

1 reference

12 December 2020

Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.

1 reference

12 December 2020

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

1 reference

12 December 2020

Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model.

1 reference

12 December 2020

Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis

1 reference

12 December 2020

Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.

1 reference

12 December 2020

Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas

1 reference

12 December 2020

Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.

1 reference

12 December 2020

Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas.

1 reference

12 December 2020

SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.

1 reference

12 December 2020

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

1 reference

12 December 2020

Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects

1 reference

12 December 2020

Role of the histone deacetylase complex in acute promyelocytic leukaemia

1 reference

12 December 2020

Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA

1 reference

12 December 2020

Histone deacetylases and cancer: causes and therapies

1 reference

12 December 2020

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol

1 reference

12 December 2020

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

1 reference

12 December 2020

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

1 reference

12 December 2020

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

1 reference

12 December 2020

Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo

1 reference

12 December 2020

Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma

1 reference

12 December 2020

Microvessel density is a prognostic indicator for patients with astroglial brain tumors.

1 reference

12 December 2020

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

1 reference

12 December 2020

Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells

1 reference

12 December 2020

Recent advances in the treatment of malignant astrocytoma

1 reference

12 December 2020

Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis

1 reference

12 December 2020

Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo

1 reference

12 December 2020

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

1 reference

12 December 2020

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

12 December 2020

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.

1 reference

12 December 2020

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

12 December 2020

10.1007/S11060-007-9337-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

18 September 2017

1018711255

0 references

1 reference